MARKET CURRENTS
real-time news and commentary for investors
- Wednesday, December 14, 2011, 4:25 PM BioSante (BPAX -15.5%) plunged in late trading, and a PR issued after the bell provides the likely reason. The company says its LibiGel drug failed to achieve its primary endpoints during Phase III trials. The company says it will continue to analyze trial data, so as to determine its next step.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
